Breast Cancer

Bionovo's phase I/II trial protocol for metastatic breast cancer accepted by U.S. FDA

Published in Oncology Business Week, December 3rd, 2006

The U.S. Food and Drug Administration (FDA) has accepted Bionovo, Inc.'s (BNVI) protocol to begin its multicenter phase 1/2 clinical trial for BZL101, the company's lead candidate for metastatic breast cancer.

The study is designed to determine the maximum tolerated dose and to evaluate the safety and efficacy of BZL101. Recruitment and testing will take place at 10 clinical sites in the U.S. The company expects to begin patient enrollment early in the first quarter of 2007. Debu Tripathy, director of the Komen/UT Southwestern Breast Cancer Research Program at the University of Texas Southwestern Medical Center in Dallas, will serve as the overall Principal...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Oncology Business Week

Source: Oncology Business Week (2006-12-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry